NONOF
NOVO NORDISK A S
$43.36
-1.88%
No data for this timeframe.
Vol
SEC Reports5
Recent Activity
Jun 5, 2026
SEC
Novo Nordisk announced that the EMA's CHMP has adopted a positive opinion recommending EU marketing authorization for We
6-K — Impact 7/10
May 27, 2026
SEC
Novo Nordisk filed a 6-K to report ongoing share repurchase activity under a pre-announced program. Since 4 February 202
6-K — Impact 3/10
Apr 13, 2026
SEC
Novo Nordisk announced a share repurchase program, buying back B shares worth DKK 2.835 billion ($383 million) from Febr
6-K — Impact 4/10
Dec 23, 2014
Event
SAXENDA
Price Targets
No recent covering-analyst activity on file. No current recommendation available.
$53.43
Current $43.36
Low $53.43
Median $53.43
High $53.43
1 analysts
$53.43
$53.43
Analyst Ratings
5Strong Buy
7Buy
23Hold
1Sell
1Strong Sell
Latest Reports
BULLISH
6-K
7/10
Novo Nordisk announced that the EMA's CHMP has adopted a positive opinion recommending EU marketing authorization for We
Jun 5, 2026
NEUTRAL
6-K
3/10
Novo Nordisk filed a 6-K to report ongoing share repurchase activity under a pre-announced program. Since 4 February 202
May 27, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.8/10.
BULLISH
6-K
7/10
Novo Nordisk announced that the EMA's CHMP has adopted a positive opinion recommending EU marketing
Jun 5, 2026
NEUTRAL
6-K
3/10
Novo Nordisk filed a 6-K to report ongoing share repurchase activity under a pre-announced program.
May 27, 2026
NEUTRAL
6-K
4/10
Novo Nordisk announced a share repurchase program, buying back B shares worth DKK 2.835 billion ($38
Apr 13, 2026
NEUTRAL
6-K
3/10
Novo Nordisk announced a share repurchase program of up to DKK 15 billion over 12 months, with DKK 2
Apr 7, 2026
NEUTRAL
6-K
2/10
Novo Nordisk A/S filed an updated version of its Articles of Association, effective March 26, 2026.
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 32% buy across 37 analysts — 5 strong buy, 7 buy, 23 hold, 1 sell, 1 strong sell. No current recommendation available.
Analyst Price Targets
No recent covering-analyst activity on file. No current recommendation available.
$53.43 mean target
$53.43 Low
$53.43 High
| Metric | Value |
|---|---|
| Current Price | $43.36 |
| Target Low | $53.43 |
| Target Mean | $53.43 |
| Target Median | $53.43 |
| Target High | $53.43 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $72.1B | -6.2% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $71.5B | -4.6% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $299.1B | 2.3% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $292.4B | -5.4% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 7 | 23 | 1 | 1 | 32% | |
| May 1, 2026 | 5 | 7 | 23 | 1 | 1 | 32% | |
| Apr 1, 2026 | 5 | 7 | 23 | 1 | 1 | 32% | |
| Mar 1, 2026 | 5 | 8 | 19 | 2 | 0 | 38% | |
| Feb 1, 2026 | 6 | 12 | 13 | 2 | 1 | 53% | |
| Jan 1, 2026 | 5 | 13 | 11 | 2 | 1 | 56% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Dec 23, 2014
FDA
SAXENDA